Roanoke Times Copyright (c) 1995, Landmark Communications, Inc. DATE: THURSDAY, March 29, 1990 TAG: 9003290641 SECTION: NATIONAL/INTERNATIONAL PAGE: A8 EDITION: EVENING SOURCE: DATELINE: DAYTONA BEACH, FLA. LENGTH: Short
The study is aimed at suppressing white patches in the mouth called leukoplakia, which can be a precursor of cancers in the mouth, pharynx, larynx and esophagus. Those cancers afflict 50,000 people a year.
The drug, called isotretinoin (Accutane), shrank growths significantly for three months and largely prevented progression during the following nine months, Dr. Scott Lippman said.
Lippman of the M.D. Anderson Cancer Center in Houston presented his results Wednesday at a science writers seminar sponsored by the American Cancer Society.
-Associated Press
by CNB